Table 1 Patient demographics and characteristics.

From: Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson’s disease in Japan

Variable

Patients (N = 96)

Age, years

62.3 (8.5)

Age categories, n (%)

   < 40 years

2 (2.1)

    40 to < 65 years

49 (51.0)

    65 to < 75 years

41 (42.7)

    ≥ 75 years

4 (4.2)

Sex, n (%)

   Male

44 (45.8)

   Female

52 (54.2)

 Time from first onset of Parkinson’s disease symptoms, years

12.5 (5.8)

 Caregiver availability, n (%)

63 (65.6)

 History of deep brain stimulation

8 (8.3)

 Hoehn and Yahr scorea

2.8 (0.9)

    Stage 1, n (%)

0 (0.0)

    Stage 2, n (%)

41 (43.6)

    Stage 3, n (%)

38 (40.4)

    Stage 4, n (%)

5 (5.3)

    Stage 5, n (%)

10 (10.6)

 MDS-UPDRS Part I total score

12.9 (5.7)

 MDS-UPDRS Part II total score

16.9 (6.8)

 MDS-UPDRS Part III total scoreb

46.1 (21.4)

    Part III bradykinesiab

14.0 (6.5)

    Part III postural instabilityb

1.4 (0.8)

    Part III upper extremity tremorb

2.2 (2.6)

 MDS-UPDRS Part IV total score

8.1 (3.5)

 MDS-UPDRS consensus-UPDRS total scorec

88.9 (23.2)

 MDS-UPDRS mean-UPDRS total scored

84.7 (21.7)

 PDQ-39 summary index

33.9 (17.3)

 Schwab and England ADL scale

73.5 (12.4)

  1. Data are mean (SD) unless reported otherwise.
  2. aAssessed in Period 2, Day 3 of inpatient assessment, OFF state.
  3. bAssessed in Period 2, Day 2 of inpatient assessment, OFF state.
  4. cConsensus scores for the MDS-UPDRS Part III were the average of three neurologist ratings (OFF medication state).
  5. dMean MDS-UPDRS Part III scores were calculated from scores on Days 2, 3, and 5 of the inpatient assessment (ON medication state).
  6. ADL Activities of Daily Living, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, PDQ-39 39-item Parkinson’s Disease Questionnaire.
Back to article page